Hikal Ltd. Q1 FY27 Earnings Call Transcript Released; FY27 Revenue Growth Expected at 14-16%
Hikal Limited reported Q1 FY27 revenue of ₹403 crore and EBITDA margin of 9.2%. The company expects FY27 revenue growth of 14-16% and EBITDA growth of 25-30%. The Pharmaceutical business is recovering, while the Animal Health business targets ₹400 crore by FY30 with 20%+ EBITDA margins. The Personal Care segment is projected to reach ₹200 crore in three years with 20%+ EBITDA margins. US FDA re-inspection is anticipated by year-end, with improved revenue and margins expected in FY28.
The announcement includes detailed financial performance for the quarter, future growth guidance, new business segment launches, and updates on critical regulatory matters (US FDA), all of which have a significant impact on investor perception and the company's future trajectory.
The company provided a positive outlook for FY27 with revenue and EBITDA growth expectations, announced the launch of a new Personal Care division, and expects significant growth in the Animal Health business. The progress on US FDA remediation also contributes to a positive sentiment.
Hikal Limited has released the transcript of its earnings conference call for the quarter ended June 30, 2026, held on August 06, 2026. The company reported revenues of ₹403 crore and an EBITDA margin of 9.2% for Q1 FY27. The Pharmaceutical business revenue stood at ₹233 crore with an EBIT margin of 3.2%, showing recovery driven by improving demand and CDMO partnerships. The company is focused on enhancing its product development capabilities, increasing DMF filings, and expanding into high-growth therapeutic segments. The Crop Protection business reported revenue of ₹170 crore with an EBIT of ₹-6 crore, facing margin pressures due to raw material costs and competition from China. However, domestic demand and CDMO volumes are expected to improve in the second half of FY27.
The Animal Health business delivered a resilient performance, with expectations to scale to over ₹400 crore by FY30, aiming for over 20% EBITDA margins. The company also commissioned a dedicated manufacturing line for its new Personal Care segment, with revenues expected by the end of the year and projected to cross ₹200 crore in three years with over 20% EBITDA margins.
Hikal has invested approximately ₹900 crore in capital expenditure over the last four years. The company has reduced its net debt from ₹815 crore in FY24 to ₹685 crore by the end of FY26, with a debt-to-equity ratio of 0.53. The company anticipates full-year revenue growth in the range of 14% to 16% for FY27, with EBITDA growth projected between 25%-30%. The company expects US FDA re-inspection towards the end of the financial year, with potential for accelerated revenue and improved margins in FY28 post-clearance.
What to do with a filing like this
Hikal Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hikal Limited. Read the original for the full detail.